Sees fourth quarter 2023 total revenue is expected to be in the range of $18.6M to $18.8M a decrease of 9% compared to the prior year period at the estimated midpoint. Surgical Glaucoma revenues are expected to be in the range of $17.1M to $17.2 M, a decrease of 9% compared to the prior year period at the estimated midpoint. Dry Eye revenues are expected to be in the range of $1.5 million to $1.6 million, a decrease of 13% compared to the prior year period at the estimated midpoint.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SGHT:
- Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
- Piper says Sight Sciences reimbursement update positive, still sees ‘work to do’
- MIGS LCD withdrawals ‘takes some upside off table’ for Glaukos, says Truist
- Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors
- Sight Sciences announces withdrawal of final LCDs on MIGS from five contractors